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Abstract
Background: Current systemic therapy for nontuberculous mycobacterial pulmonary infection is
limited by poor clinical response rates, drug toxicities and side effects. The addition of aerosolized
amikacin to standard oral therapy for nontuberculous mycobacterial pulmonary infection may
improve treatment efficacy without producing systemic toxicity. This study was undertaken to
assess the safety, tolerability and preliminary clinical benefits of the addition of aerosolized amikacin
to a standard macrolide-based oral treatment regimen.
Case Presentations: Six HIV-negative patients with Mycobacterium avium intracellulare pulmonary
infections who had failed standard therapy were administered aerosolized amikacin at 15 mg/kg
daily in addition to standard multi-drug macrolide-based oral therapy. Patients were monitored
clinically and serial sputum cultures were obtained to assess response to therapy. Symptomatic
improvement with radiographic stabilization and eradication of mycobacterium from sputum were
considered markers of success.
Of the six patients treated with daily aerosolized amikacin, five responded to therapy. All of the
responders achieved symptomatic improvement and four were sputum culture negative after 6
months of therapy. Two patients became re-infected with Mycobacterium avium intracellulare after 7
and 21 months of treatment. One of the responders who was initially diagnosed with
Mycobacterium avium intracellulare became sputum culture positive for Mycobacterium chelonae
resistant to amikacin after being on intermittent therapy for 4 years. One patient had progressive
respiratory failure and died despite additional therapy. There was no evidence of nephrotoxicity or
ototoxicity associated with therapy.
Conclusion: Aerosolized delivery of amikacin is a promising adjunct to standard therapy for
pulmonary nontuberculous mycobacterial infections. Larger prospective trials are needed to define
its optimal role in therapy of this disease.
Background
Nontuberculous mycobacterial (NTM) pulmonary infec-
tion is now recognized as a serious disease in a subset of
apparently immunocompetent hosts [1-4]. Though ini-
tially described as a disease of Caucasian women, its
reported incidence is increasing in other populations such
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as nonwhites and patients in urban areas, possibly as a
result of increased disease awareness and improved clini-
cal investigation efforts. In North America infection rates
are approaching 15 per 100,000[5]. Mycobacterium avium
complex (MAC) has been reported most commonly, fol-
lowed by rapid grower mycobacterium (RGM) (M. chelo-
nae, M. abscessus and M. fortuitum) and M kansasii [2].
NTM disease manifestation depends on a complex inter-
action between specific mycobacterial pathogens and the
host immune system. Preliminary data has suggested
interferon-gamma deficient pathways, presence of a cystic
fibrosis gene mutation and alpha-1 antiproteinase gene
mutations as possible predisposing factors for pulmonary
disease development in immunocompetent patients with-
out underlying lung disease[3,6] Of particular interest is
the increasing incidence of MAC lung infections character-
ized by progressive parenchymal lung disease in middle
aged and elderly women with no history of smoking or
underlying lung disease[7].
Currently, the accepted standard therapy for patients with
MAC infection involves the use of a macrolide-based
multi-drug regimen consisting of a macrolide or azalide
(clarithromycin or azithromycin), a rifamycin (rifabutin
or rifampin) and ethambutol, with or without the initial
inclusion of intravenous streptomycin or amikacin. Ami-
kacin (intravenous) and other antibiotics such as fluoro-
quinolones have largely been reserved for patients with
more advanced disease or as salvage therapy[8,9]. Rapid
growers such as M. chelonae and M. abscessus are even
more difficult to treat and usually require complex medi-
cal regimens which include intravenous antibiotics such
as cefoxitin, amikacin, imipenem, and linezolid in addi-
tion to oral macrolide therapy. The available data on ther-
apy demonstrates that successful eradication of MAC
pulmonary infection after 12 months of therapy is
achieved in only 50–71% of HIV-negative
patients[3,10,11]. Successful therapy has been hampered
by potential drug-drug interactions, poor tolerance, toxic-
ity and relapse after completion of treatment [12]. More
effective treatment strategies are needed for optimal con-
trol of these infections.
Aminoglycosides, particularly amikacin, have been rec-
ommended and variably used for limited duration (less
than 4 to 6 months) parenteral therapy for NTM infec-
tions. The aminoglycosides exhibit significant concentra-
tion-dependent bactericidal activity against NTM. More
extended parenteral therapy duration has been avoided
due to the substantial risks of nephrotoxicity (15%), oto-
toxicity (37%) and vestibular toxicity (9%)[13]. Aerosol
antibiotic delivery offers the potential advantage of
achieving high lung drug concentrations with concomi-
tant low systemic absorption, low serum drug concentra-
tions, and thus a diminished risk of systemic
toxicities[14]. In a small intensive care unit study[15], aer-
osolized amikacin delivered to mechanically ventilated
patients at doses of 400 mg every 8 hours resulted in mean
peak sputum concentrations of more than 5,000 mcg/ml,
an impressive level that would be completely unachieva-
ble (and toxic) when delivered systemically. Aerosolized
antibiotics have been used with notable success in the
treatment of chronic infection with Pseudomonas aerugi-
nosa  in cystic fibrosis[14,16]. Recent studies have
expanded on this concept and have demonstrated safety
and tolerance of inhaled tobramycin solution for inhala-
tion in the management of non-cystic fibrosis patients
with severe bronchiectasis[17]. These studies were able to
demonstrate a decrease in the number of hospitalizations,
improvement in respiratory symptoms and in health
related quality of life[18]. Inhaled aminoglycosides (gen-
tamycin, kanamycin and streptomycin) have also been
reported to provide benefit when used as a salvage therapy
in complex and refractory pulmonary tuberculosis infec-
tions [19,20].
The addition of aerosolized amikacin to standard oral
therapy for NTM pulmonary infection has the potential to
improve treatment efficacy without increasing the risk for
systemic toxicity. Inhaled amikacin has been considered
as adjunctive therapy for pulmonary NTM infections for a
number of years, and has been used in very limited cir-
cumstances, but no formal evaluation of the pharmacoki-
netics, tolerability or therapeutic efficacy of inhaled
amikacin has been undertaken. This current investigation
reports the pharmacokinetics of inhaled amikacin in
adults, as well as our preliminary experience with inhaled
amikacin therapy in a small patient cohort with pulmo-
nary NTM infection.
Case Presentations
Treatment subjects were identified from the population of
patients with pulmonary NTM infections followed and
treated at the Stanford University Medical Center Chest
Clinic. All patients included in this series had a diagnosis
of NTM infection that met the disease diagnostic criteria
established in the 1997 ATS consensus statement[9].
These patients had remained sputum culture positive
despite a minimum of six months of standard oral therapy
with a macrolide-based multi-drug regimen. All of the
patients included in this case series were symptomatic and
had radiographic evidence of nodular infiltrates, bron-
chiectasis and/or cavitary disease as outlined in Table 1.
Institutional approval for inhaled amikacin delivery was
obtained, as was informed consent from all study sub-
jects.
Patients were treated with aerosolized amikacin as a single
daily dose of 15 mg/kg administered using a DeVilbiss
PulmoAide Compressor/Nebulizer system (DeVilbissB
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Table 1: Case Data Summaries
Pt. No Sex, Age 
(Years)
NTM 
Species
Radiographic Pattern Duration of 
therapy prior 
to starting 
amikacin 
(months)
Amikacin 
Therapeutic 
Regimen
Duration 
of Inhaled 
Amikacin 
(months)
Current Therapeutic 
Regimen
Current Patient 
Status
Current Sputum 
Culture Status
1 F, 73 MAC nodular infiltrates, bronchiectasis in 
RUL, RML, lingula
96 CLA, RIF, EMB, 
inhaled amikacin
9 no oral antibiotics since 
7/05; no inhaled 
amikacin since 6/06.
rare cough, wt loss, 
sweats, fatigue; 
abdominal cramps
negative for 21 
months; now positive 
(MAC)
2 F, 67 MAC bilateral bronchiectasis, cavitary 
lesion RUL and bilateral apical 
fibrosis/scarring
12 AZI, RIF, EMB, inhaled 
amikacin
4 n/a progressive disease; 
died
persistent positive at 
death
3F ,  6 6 M A C ,  M. 
chelonae
bronchiectasis RML, RLL, LLL, lingula; 
bilateral apical fibrosis/scarring, 
centrilobular nodules
48 AZI, RIF, EMB, inhaled 
amikacin
52 AZI 500 mg/d since 4/06 status post multiple 
lobectomies; cough 
and exertional 
dyspnea; daily low 
grade fevers
negative for 6 
months., now 
positive; M. chelonae 
(resistant to amikacin
4 F, 71 MAC bronchiectasis and centrilobular 
nodules in posterior segments of 
both upper lobes, RML, lingula and 
lower lobes
36 CLA, inhaled amikacin 16 no antibiotics since 11/
05
rare cough negative for 7 months; 
now positive; MAC 
(resistant to EMB, 
RIF)
5F ,  5 2 M A C ,  M. 
chelonae
LUL wedge resection for MAC; 
bronchiectasis in LLL, RUL; R apical 
scarring, nodules in LLL, LUL, lingula
0.5 AZI, inhaled amikacin 
(thrombocytopenia on 
RIF/EMB)
13 inhaled amikacin 1000 
mg/d and AZI 250 mg/d 
since 5/05
improved with some 
cough, no purulence
negative for 6 mo.
6 F, 54 MAC bronchiectasis w/bronchial wall 
thickening RLL, RUL.
13 AZI, inhaled amikacin 8 AZI 500 mg 2/wk, 
inhaled amikacin 1000 
mg 3/wk
rare cough, clinically 
well
no cough sputum 
(despite sputum 
induction)
Abbreviations: AZI (azithromycin); CIP (ciprofloxacin); CLA (clarithromycin); EMB (ethambutol); RIF(rifampin); RUL (right upper lobe); RML (right middle lobe); RLL (right lower lobe); LLL (left lower lobe)BMC Pulmonary Medicine 2007, 7:2 http://www.biomedcentral.com/1471-2466/7/2
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Health Care; Somerset, Pa) in addition to their concurrent
oral antibiotic regimens. Amikacin therapy was antici-
pated to continue for the duration of their oral antibiotic
course (estimated 12–18 month course). Patients were
pre-treated with an albuterol meter dose inhaler, if they
developed shortness of breath or cough with aerosolized
amikacin administration.
An inhaled amikacin dose of 15 mg/kg/day was chosen
with the following considerations: a) 15 mg/kg is the
usual total daily IV dose for therapy with amikacin; b) the
goal of inhaled amikacin therapy was to produce lung
drug concentrations that significantly exceed minimum
inhibitory concentration (MIC), with particular attention
to patients with significant anatomic lung problems
including bronchiectasis, where lung drug distribution
may be much less uniform than in normal lung.
None of the study patients were currently receiving intra-
venous aminoglycoside therapy. Patients were monitored
throughout therapy for evidence of nephrotoxicity, oto-
toxicity and vestibuar toxicity. Clinical improvement was
determined on the basis of a combination of the follow-
ing: symptomatic improvement, radiographic stabiliza-
tion or improvement, and eradication of mycobacterium
from sputum cultures. Sputum cultures were performed at
8 to 12 week intervals and were induced with hypertonic
saline if the patient's cough was non-productive. Aero-
solized amikacin was held for 24 hours prior to sputum
induction for surveillance cultures.
Six patients with NTM pulmonary infections were treated
with aerosolized amikacin at a dose of 15 mg/kg/day in
addition to a concurrent standard oral macrolide based
multi-drug regimen. Table 1 outlines specific patient char-
acteristics. All of the patients were women between the
ages of 52 and 71 years. All had been treated previously
with standard oral macrolide/rifamycin-based regimens
and either had failed to respond or were unable to tolerate
therapy due to side effects. Patient 4 was infected with a
MAC species that was resistant to ethambutol and
rifampin, necessitating a change in medications. All
remained symptomatic despite prior interventions and
had progressive or persistent symptoms including fatigue,
cough, hemoptysis, dyspnea, and weight loss. None of the
patients had known macrolide resistant NTM infections.
Each had a different radiographic presentation on chest
radiograph and CT. Patient 1 had primarily nodular infil-
trates with mild multi-lobar bronchiectasis; patient 2 had
severe multi-lobar bronchiectasis and cavitary nodules;
patient 3 had multi-lobar bronchiectasis, centrilobular
nodules and a history of a right middle lobe and lingual
resection; patient 4 had mild multi-lobar bronchiectasis
and diffuse centrilobular nodules; patient 5 had multi-
lobar bronchiectasis, centrilobular nodules and a history
of a left upper lobe wedge resection; patient 6 had focal
bronchiectasis and bronchial wall thickening confined to
the right upper and lower lobes. Patients received an aver-
age of 750 mg to 1000 mg/day of aerosolized amikacin
based on weight.
Patients 1, 3, 4, 5 and 6 tolerated therapy well. They all
noted an improvement in cough and fatigue with therapy
and were sputum culture negative for NTM on follow-up
cultures after 6 months of therapy. Patient 3 developed
recurrent NTM disease after 6 months of culture-negative
sputum. Her initial sputum cultures prior to initiating
inhaled amikacin therapy revealed MAC; subsequent cul-
tures have grown M. chelonae and M. gordonae. Patient 2
was unable to tolerate prolonged therapy with aerosolized
amikacin and discontinued therapy after 4 months
because of cough and inconvenience of administration.
She continued to experience progressive symptoms after
cessation of therapy and died of respiratory failure.
Side effects of therapy included voice hoarseness, sore
throat (transient) and oral candidiasis. Two patients
developed oral candidiasis on aerosolized amikacin ther-
apy that was not responsive to Nystatin oral rinse. Both
cases responded well to oral fluconazole therapy. Subse-
quent episodes of oropharyngeal problems were pre-
vented with improved vigilance of mouth care (including
mouth gargling as well as rinsing) after each dose admin-
istration. There was no evidence of nephrotoxicity, oto-
toxicity or vestibular toxicity with therapy.
Conclusion
The treatment of NTM pulmonary infections has been
punctuated by intolerance of therapy, side effects and
recurrence of infection. The addition of aerosolized ami-
kacin at 15 mg/kg/day to a standard oral macrolide-based
regimen led to successful treatment of NTM pulmonary
disease in 66.7% (4/6) of patients treated. Aerosolized
amikacin, at the dose used in this case series, is well toler-
ated, lacks any evidence of systemic toxicity (particularly
ototoxicity and nephrotoxicity) and is of potential benefit
in patients who have failed or were intolerant of standard
macrolide-based therapy. Patients with prior therapeutic
failures are notable for their typically poor response rates
with subsequent treatment regimens, which make the pre-
liminary responses seen in this study even more signifi-
cant. Most of our patients demonstrated clinical
improvement in symptoms on aerosolized amikacin with
diminished cough, sputum production and fatigue.
Patients who failed to respond to inhaled amikacin ther-
apy in our case series had more extensive parenchymal
involvement and cavitary disease on high resolution CT
(HRCT) scans, were sputum culture positive for M. chelo-
nae, and/or received inhaled amikacin therapy for less
than four months.BMC Pulmonary Medicine 2007, 7:2 http://www.biomedcentral.com/1471-2466/7/2
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Patients with NTM infections and extensive parenchymal
involvement are known to have poorer outcomes [3]. Suc-
cessful clearance of organisms becomes more difficult in
the face of a combination of potentially very important
factors including altered lung anatomy and function, and
patients' inherent increased susceptibility to NTM. As a
result, the likelihood of relapse and/or re-infection with
other NTM is quite substantial [21,22]. In our case series,
patient 3 had MAC and later developed M. chelonae after
clearing her initial infection and patient 5 was co-infected
with both organisms at the onset of treatment, which also
raises the question of differing susceptibilities and
response to treatment depending on the organism.
There is an increasing view among investigators, particu-
larly related to inhaled aminoglycoside therapy in cystic
fibrosis, that increased delivered drug dose, and the result-
ant increased lung drug concentrations, might be associ-
ated with improved therapeutic utility. In an independent
study performed by our group, aerosolized amikacin
administered to healthy volunteers at a dose of 5 mg/kg,
produced sputum concentrations of 25–298 mcg/ml 1-
hour post administration. These sputum concentrations
far exceed the MIC90 of amikacin for the vast majority of
NTM isolates[23], while producing serum amikacin con-
centrations that are at or below the accepted range for
trough concentrations produced by intravenous amikacin
administration[13-15,24]. These results are consistent
with those published for the use of inhaled tobramycin,
where measured serum levels after inhaled drug delivery
remain very low, even with doses that exceed usual total
daily parenteral doses[16].
This study has a number of limitations. The reported fol-
low-up of patients in our case series occurred over a 9–52
month period. Longer follow-up of each patient may be
needed to fully assess disease recurrence (either by re-
infection or by reactivation of suppressed initial infec-
tion) over time in responders, particularly given the
apparent increased inherent susceptibility of these
patients to NTM infections. In our study, aerosolized ami-
kacin was administered using a DeVilbiss PulmoAide
Compressor/Nebulizer system (DeVilbiss Health Care;
Somerset, Pa). We do not know the aerosol droplet size
that would be best to generate optimal distribution of
amikacin in patients with pulmonary NTM infection.
Other aerosol delivery systems may be of equal or greater
utility for amikacin delivery in these circumstances.
Aerosolized amikacin is a promising addition to the cur-
rent therapies used for the treatment of pulmonary NTM
infections. It is well tolerated and in our series was able to
stabilize or clinically improve patients who had failed
standard macrolide-based NTM therapy. We have not
addressed a number of important additional aspects of
the use of aerosolized amikacin in this disease, including
the optimal dose, optimal treatment duration, or the opti-
mal concomitant drug regimen to be used with inhaled
amikacin. The question of whether earlier and/or more
aggressive treatment for NTM infection in this patient
population would lead to decreased morbidity and
improved outcomes also cannot be answered by this
study. These are, however, extremely important questions
that will be best addressed in a larger, randomized, pro-
spective treatment trial.
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